{
    "organizations": [],
    "uuid": "46b5d797f324a79712bb534fffc4e00b1a86968a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-inventiva-announces-us-phase-ii-in/brief-inventiva-announces-u-s-phase-ii-investigator-initiated-study-with-lanifibranor-idUSASO0002Y3",
    "ord_in_thread": 0,
    "title": "BRIEF-Inventiva Announces U.S. Phase II Investigator-Initiated Study With Lanifibranor",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 4 (Reuters) - Inventiva SA:\n* INVENTIVA ANNOUNCES A U.S. PHASE II INVESTIGATOR-INITIATED STUDY WITH LANIFIBRANOR ON NON ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES\n* DR. KENNETH CUSI OF UNIVERSITY OF FLORIDA TO BE PRINCIPAL INVESTIGATOR\n* TRIAL IN 64 PATIENTS TO BEGIN AFTER FDA HAS APPROVED LANIFIBRANOR IND Source text for Eikon: Further company coverage: (Gdynia Newsroom:)\n ",
    "published": "2018-04-04T23:51:00.000+03:00",
    "crawled": "2018-04-05T17:17:22.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "inventiva",
        "sa",
        "inventiva",
        "announces",
        "phase",
        "ii",
        "study",
        "lanifibranor",
        "non",
        "alcoholic",
        "fatty",
        "liver",
        "disease",
        "patient",
        "type",
        "diabetes",
        "kenneth",
        "cusi",
        "university",
        "florida",
        "principal",
        "investigator",
        "trial",
        "patient",
        "begin",
        "fda",
        "approved",
        "lanifibranor",
        "ind",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}